A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.

BMC Cancer · 2021 · PMC8306282 · PMID 34301221

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

Activation of immune mechanisms is also likely to be significant in CXD101’s action.

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.